0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Immune Checkpoint Proteins > PD-1 > PD1-H82F4

Biotinylated Human PD-1 / PDCD1 Protein, Fc,Avitag™,His Tag (MALS verified)

  • Synonym
    PDCD1,PD1,CD279,SLEB2
  • Source
    Biotinylated Human PD-1, Fc,Avitag,His Tag (PD1-H82F4) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Gln 167 (Accession # Q15116-1).
    Predicted N-terminus: Leu 25
  • Molecular Characterization
    Online(Leu 25 - Gln 167) Q15116-1

    This protein carries a human IgG1 Fc fragment at the C-terminus, followed by a polyhistidine tag. The Avi tag (Avitag™) is inserted in-between the Fc and his tags.

    The protein has a calculated MW of 45.5 kDa. As a result of glycosylation, the protein migrates as 55-65 kDa under reducing (R) condition, and 115-130 kDa under non-reducing (NR) condition (SDS-PAGE).

  • Biotinylation
    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
  • Biotin:Protein Ratio
    The biotin to protein ratio is 0.5-1 as determined by the HABA assay.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 . Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Biotinylated Human PD-1, Fc,Avitag,His Tag (Cat. No. PD1-H82F4) SDS-PAGE gel

Biotinylated Human PD-1, Fc,Avitag,His Tag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS
Biotinylated Human PD-1, Fc,Avitag,His Tag (Cat. No. ) MALS images

The purity of Biotinylated Human PD-1, Fc,Avitag,His Tag(Cat. No. PD1-H82F4) was more than 90% and the molecular weight of this protein is around 125-140 kDa verified by SEC-MALS.

Bioactivity-ELISA
Biotinylated Human PD-1, Fc,Avitag,His TagBiotinylated Human PD-1, Fc,Avitag,His Tag (Cat. No. PD1-H82F4) ELISA bioactivity

Immobilized Human PD-L1, Fc Tag (HPLC-verified) (Cat. No. PD1-H5258) at 5 μg/mL (100 μL/well) can bind Biotinylated Human PD-1, Fc,Avitag,His Tag (Cat. No. PD1-H82F4) with a linear range of 10-156 ng/mL (QC tested).

Biotinylated Human PD-1, Fc,Avitag,His TagBiotinylated Human PD-1, Fc,Avitag,His Tag (Cat. No. PD1-H82F4) ELISA bioactivity

Immobilized Human PD-L2, Fc Tag (HPLC verified) (Cat. No. PD2-H5251) at 5 μg/mL (100 μL/well) can bind Biotinylated Human PD-1, Fc,Avitag,His Tag (Cat. No. PD1-H82F4) with a linear range of 10-40 ng/mL (Routinely tested).

Biotinylated Human PD-1, Fc,Avitag,His TagBiotinylated Human PD-1, Fc,Avitag,His Tag (Cat. No. PD1-H82F4) ELISA bioactivity

Immobilized Nivolumab at 5 μg/mL (100 μL/well) can bind Biotinylated Human PD-1, Fc,Avitag,His Tag (Cat. No. PD1-H82F4) with a linear range of 0.1-3 ng/mL (Routinely tested).

Biotinylated Human PD-1, Fc,Avitag,His TagBiotinylated Human PD-1, Fc,Avitag,His Tag (Cat. No. PD1-H82F4) ELISA bioactivity

Serial dilutions of Anti-PD-L1 Neutralizing Antibody were added into Human PD-L1, Fc Tag (HPLC-verified) (Cat. No. PD1-H5258): Biotinylated Human PD-1, Fc,Avitag,His Tag (Cat. No. PD1-H82F2) binding reactions. The half maximal inhibitory concentration (IC50) is 0.2394 μg/mL (Routinely tested).

Bioactivity-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human PD-1, Fc,Avitag,His Tag (Cat. No. PD1-H82F4) on SA Biosensor, can bind Human PD-L1, His Tag (HPLC verified) (Cat. No. PD1-H5229) with an affinity constant of 1.6 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human PD-1, Fc,Avitag,His Tag (Cat. No. PD1-H82F4) on SA Biosensor, can bind PD-L2, His Tag (SPR verified) (Cat. No. PD2-H5220) with an affinity constant of 0.42 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

  • Background
    Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.
  • Clinical and Translational Updates
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $350.00

Price(USD) : $1380.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:8 Details
  • Number of Drugs in Clinical Trials:73 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop